Prima Biomed Limited Company Profile - Sep 06, 2011 by WrightReports


More Info
									Company Fundamentals\Company Profile

   A Wright Investors' Service Research Report:

   Prima Biomed Limited
                                                                                          440 Wheelers Farms Road
                                                                                          Milford, CT 06461 U.S.A.

  Figures in Australian Dollars

                                 Wright Quality Rating:DCNN                                 Key Data

   Prima Biomed Limited is a biotechnology company with a portfolio of products             Ticker:
   focused in the therapeutic area of cancer. The principal activities of the Company,      PRR
   during the fiscal year ended June 30, 2010, were research and commercialization of
   licensed medical biotechnology through its subsidiaries. The Company has three           2011 Sales:
   projects: Cvac, Cripto-1 Antibody and HPV Vaccine. The CVac is a cancer vaccine
   product consists of an adjuvant, mannan, attached to a tumor cell surface protein,
   mucin 1. The CVac focuses on Phase IIb trials to confirm the ability of CVac to
   reduce the instance of relapse in ovarian cancer patients, control the metastases of     Major Industry:
   the cancer and increase the life expectancy of patients. In May Prima entered into       Miscellaneous
   an agreement with German institute, the Fraunhofer Institute for Cell Therapy and
   Immunology (Fraunhofer IZI) in Leipzig, Germany, to produce the CVac cancer              Sub Industry:
   immunotherapy vaccine for the Company's European clinical trials. Cripto-1 Antibody      Medical Services
   is a human antibody.
                       Stock Chart                                   Officers               Country:
                                                                     Chairman               Australia
                                                                  Lucy H. Turnbull
                                                                  Vice Chairman
                                                                                            Australian Dollars
                                                                  Yue-Ling Wong

                                                                                    Fiscal Year Ends:
                                                         Chief Executive & Managing
                                                                   Director         June
                                                            Martin Frederick Rogers
                                                           Chief Operating Officer  1
                                                                  Matthew Lehman
                                                              Chief Financial Officer &     OTC
                                                                     Ian E. Bangs           Share Type:

To top